Zoely

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Nomegestrol acetat, estradiol

Available from:

Theramex Ireland Limited

ATC code:

G03AA14

INN (International Name):

nomegestrol, estradiol

Therapeutic group:

Spolni hormoni in zdravila genitalni sistem,

Therapeutic area:

Kontracepcija

Therapeutic indications:

Oral contraception,.

Product summary:

Revision: 23

Authorization status:

Pooblaščeni

Authorization date:

2011-07-26

Patient Information leaflet

                                26
Imetnik dovoljenja za promet z zdravilom:
Theramex Ireland Limited
3
rd
Floor, Kilmore House,
Park Lane, Spencer Dock,
Dublin 1
D01 YE64
Irska
EU/1/11/690/001 28 filmsko obloženih tablet
EU/1/11/690/002 84 filmsko obloženih tablet
EU/1/11/690/003 168 filmsko obloženih tablet
EU/1/11/690/004 364 filmsko obloženih tablet
Lot
zoely
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
PC
SN
NN
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
13.
ŠTEVILKA SERIJE
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
27
Zoely 2,5 mg/1,5 mg tablete
nomegestrolacetat/estradiol
Theramex Ireland Limited
EXP
Lot
[okvirček za dnevno oznako z napisom:] sem prilepite nalepko z
dnevnimi oznakami
[številka dneva za vsako posamezno tableto:] začetek, 2, ….28
[puščice kažejo zaporedje jemanja tablet:]
→
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
4.
ŠTEVILKA SERIJE
5.
DRUGI PODATKI
28
List dnevnih oznak
Izberite dnevno oznako, ki se začne z dnevom, ko boste začeli jemati
zdravilo.
Oznako prilepite na pretisni omot čez besede "sem prilepite nalepko z
dnevnimi oznakami".
NED PON TOR SRE ČET PET SOB
PON TOR SRE ČET PET SOB NED
TOR SRE ČET PET SOB NED PON
SRE ČET PET SOB NED PON TOR
ČET PET SOB NED PON TOR SRE
PET SOB NED
PON TOR SRE ČET
SOB NED
PON TOR SRE ČET PET
[Drugi list dnevnih oznak za škatlo s 3 pretisnimi omoti, kjer je
dvakrat napisano:]
[pred dnevnimi oznakami za drugi pretisni omot:] 2. pretisni omot
[pred dnevnimi oznakami za tretji pretisni omot:] 3. pretisni omot
LIST DNEVNIH OZNAK Z NALE
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Zoely 2,5 mg/1,5 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena bela tableta z učinkovino vsebuje 2,5 mg nomegestrolacetata in
1,5 mg estradiola (v obliki
hemihidrata).
Rumene placebo tablete ne vsebujejo učinkovin.
Pomožne snovi z znanim učinkom
Ena bela tableta z učinkovino vsebuje 57,7 mg laktoze monohidrata.
Ena rumena placebo tableta vsebuje 61,8 mg laktoze monohidrata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Tableta z učinkovino je bela, okrogla, z oznako "ne" na obeh straneh.
Placebo tableta je rumena, okrogla, z oznako "p" na obeh straneh
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
peroralna kontracepcija
Pri odločitvi, da predpišete zdravilo Zoely, je treba upoštevati
trenutne dejavnike tveganja pri
posameznici, zlasti za vensko trombembolijo (VTE) in kakšno je
tveganje za VTE pri zdravilu Zoely v
primerjavi z drugimi kombiniranimi hormonskimi kontraceptivi (CHC –
_combined hormonal _
_contraceptives_
) (glejte poglavji 4.3 in 4.4).
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Ženska naj 28 zaporednih dni jemlje po eno tableto na dan. Vsak
pretisni omot se začne s 24 belimi
tabletami z učinkovino, nato sledijo 4 rumene placebo tablete.
Tablete iz naslednjega omota naj začne
ženska jemati takoj, ko konča s prejšnjim, brez premora v
vsakodnevnem jemanju tablet in neodvisno
od tega, ali ima odtegnitveno krvavitev ali ne. Odtegnitvena krvavitev
se običajno pojavi na
2. do 3. dan po zaužitju zadnje bele tablete in morda še ne bo
končana, ko bo ženska že začela jemati
tablete iz naslednjega pretisnega omota. Glejte tudi "Nadzor ciklusa"
v poglavju 4.4.
_Posebne populacije _
_ _
_Okvara ledvic _
Čeprav podatki o bolnicah z okvaro ledvic niso na voljo, je malo
verjetno, da bi okvara ledvic vplivala
na izločanje nomegestrolacetata in estradiola.
3
_Okvara jeter _
Klinične študije pri bolnicah z jetrno insuficienco nis
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-12-2022
Public Assessment Report Public Assessment Report Bulgarian 17-05-2016
Patient Information leaflet Patient Information leaflet Spanish 16-12-2022
Public Assessment Report Public Assessment Report Spanish 17-05-2016
Patient Information leaflet Patient Information leaflet Czech 16-12-2022
Public Assessment Report Public Assessment Report Czech 17-05-2016
Patient Information leaflet Patient Information leaflet Danish 16-12-2022
Public Assessment Report Public Assessment Report Danish 17-05-2016
Patient Information leaflet Patient Information leaflet German 16-12-2022
Public Assessment Report Public Assessment Report German 17-05-2016
Patient Information leaflet Patient Information leaflet Estonian 16-12-2022
Public Assessment Report Public Assessment Report Estonian 17-05-2016
Patient Information leaflet Patient Information leaflet Greek 16-12-2022
Public Assessment Report Public Assessment Report Greek 17-05-2016
Patient Information leaflet Patient Information leaflet English 16-12-2022
Public Assessment Report Public Assessment Report English 17-05-2016
Patient Information leaflet Patient Information leaflet French 16-12-2022
Public Assessment Report Public Assessment Report French 17-05-2016
Patient Information leaflet Patient Information leaflet Italian 16-12-2022
Public Assessment Report Public Assessment Report Italian 17-05-2016
Patient Information leaflet Patient Information leaflet Latvian 16-12-2022
Public Assessment Report Public Assessment Report Latvian 17-05-2016
Patient Information leaflet Patient Information leaflet Lithuanian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-12-2022
Public Assessment Report Public Assessment Report Lithuanian 17-05-2016
Patient Information leaflet Patient Information leaflet Hungarian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 16-12-2022
Public Assessment Report Public Assessment Report Hungarian 17-05-2016
Patient Information leaflet Patient Information leaflet Maltese 16-12-2022
Public Assessment Report Public Assessment Report Maltese 17-05-2016
Patient Information leaflet Patient Information leaflet Dutch 16-12-2022
Public Assessment Report Public Assessment Report Dutch 17-05-2016
Patient Information leaflet Patient Information leaflet Polish 16-12-2022
Public Assessment Report Public Assessment Report Polish 17-05-2016
Patient Information leaflet Patient Information leaflet Portuguese 16-12-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 16-12-2022
Public Assessment Report Public Assessment Report Portuguese 17-05-2016
Patient Information leaflet Patient Information leaflet Romanian 16-12-2022
Public Assessment Report Public Assessment Report Romanian 17-05-2016
Patient Information leaflet Patient Information leaflet Slovak 16-12-2022
Public Assessment Report Public Assessment Report Slovak 17-05-2016
Patient Information leaflet Patient Information leaflet Finnish 16-12-2022
Public Assessment Report Public Assessment Report Finnish 17-05-2016
Patient Information leaflet Patient Information leaflet Swedish 16-12-2022
Public Assessment Report Public Assessment Report Swedish 17-05-2016
Patient Information leaflet Patient Information leaflet Norwegian 16-12-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 16-12-2022
Patient Information leaflet Patient Information leaflet Icelandic 16-12-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 16-12-2022
Patient Information leaflet Patient Information leaflet Croatian 16-12-2022
Public Assessment Report Public Assessment Report Croatian 17-05-2016

Search alerts related to this product

View documents history